Keywords: Ipsen, Third quarter 2009 results
France’s Ipsen sees strong 3rd quarter and nine month 2009 performance
Article | 29 October 2009
French biopharmaceutical company Ipsen reported a 5.8% rise in sales in the first nine months of 2009, at 777.5 million euros ($1.17 billion), with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
